The 340B program was not a focus of today’s Senate HELP hearing on President Trump’s drug pricing blueprint entitled “American Patients First: The Trump Administration Blueprint to Lower Drug Prices and Reduce Out-of-Pocket Costs.” The blueprint included a set of policy proposals regarding the 340B program; however, HHS Secretary Alex Azar did not focus his testimony on the 340B program. The only Senator who mentioned the 340B program was Sen. Mike Enzi (R-WY) who indicated he would submit questions related to the program into the record. Senators focused their comments and questions to Secretary Azar on whether and how the blueprint could lower drug prices and included discussions about Medicare negotiations of drug prices. The President’s drug pricing plan solicited public comments on a number of 340B questions, including whether the program’s growth is affecting list prices and whether current mechanisms for preventing duplicate discounts are effective. Comments on the blueprint are due July 16, 2018.